Improving the health and well being of patients affected by Alzheimer's disease

News
August 25, 2023

Improving the health and well being of patients affected by Alzheimer’s disease

Ram Mukunda and Claudia Grimaldi, representing IGC Pharma, a pharmaceutical company in the clinical stage dedicated to enhancing the health of Alzheimer's disease patients and making these treatments accessible, appear on eHealth Radio and the Alzheimer's Information and Health News Channels.

Recent Post

IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow

June 23, 2026

Psilocybin and Mental Health

June 18, 2026

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

June 11, 2026

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

June 9, 2026

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

June 2, 2026

IGC Pharma’s AHA Agentic AI Platform Reduces Alzheimer’s Data Harmonization Time by 90% in Representative Workflow

Patent-pending multi-agent architecture targets fragmented biomedical data and expands toward imaging, omics, and broader health-data applications ahead of planned AAIC 2026 demonstration in London

Psilocybin and Mental Health

Psilocybin, a psychedelic compound in “magic mushrooms,” has shown potential in treating refractory depression, addiction, and terminal cancer-related anxiety. Although early studies show promising results, further research is needed to

IGC Pharma Reaches Previously Disclosed 146-Patient Enrollment Target in Phase 2 CALMA Trial, Advancing Toward Topline Analysis

Company continuing limited over-enrollment activities to account for attrition and support robust modified intent-to-treat, end-of-treatment, and exploratory analyses

Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts

POTOMAC, Maryland – June 9, 2026 – IGC Pharma, Inc. (NYSE American: IGC) (“IGC” or the “Company”), a clinical-stage biotechnology company developing therapeutics for Alzheimer’s disease, today announced that Ascendiant Capital Markets

IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis

Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis

Improving the health and well being of patients affected by Alzheimer’s disease

Follow Us

Subscribe to Our Newsletter